# Surovatamig as Consolidation Therapy in Participants With Chronic Lymphocytic Leukaemia or Small Lymphocytic Lymphoma With Unmutated Immunoglobulin He

Source: https://onco.cc/trials/nct07509151/  
OnCo record `nct07509151` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 3 trial of AZD0486 in chronic lymphocytic leukaemia, run by AstraZeneca, now recruiting.

## Summary

Surovatamig as Consolidation Therapy in Participants With Chronic Lymphocytic Leukaemia or Small Lymphocytic Lymphoma With Unmutated Immunoglobulin Heavy Chain Variable (IGHV) is a phase 3 interventional study registered as NCT07509151 by AstraZeneca, with 420 participants planned, started 2026-05-05 and due to reach its primary completion in 2031-08-29. Interventions recorded: Surovatamig. Conditions listed: Chronic Lymphocytic Leukaemia or Small Lymphocytic Lymphoma With Unmutated IGHV. No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-16
- Tags: ctgov-ingest
- Registry id: NCT07509151
- Phase: 3
- Setting: A Phase III, Randomised, Open-label, Multicentre, Study of Surovatamig as Consolidation Therapy Versus Observation After First-line Induction Therapy in Participants With Chronic Lymphocytic Leukaemia or Small Lymphocytic Lymphoma With Unmutated IGHV (SOUNDTRACK-C1)
- Sponsor: AstraZeneca
- Enrolled: 420

## Sources

- ClinicalTrials.gov NCT07509151: https://clinicaltrials.gov/study/NCT07509151

## Connected records

- cancers: [Chronic lymphocytic leukaemia](https://onco.cc/cancers/cll/)
- drugs: [AZD0486](https://onco.cc/drugs/azd0486/)
- companies: [AstraZeneca](https://onco.cc/companies/astrazeneca/)

---
JSON: https://onco.cc/api/v1/entities/nct07509151.json